For the latest updates on how we are managing changes due to COVID-19 please click here.

Keynote: 2021 International Congress of Ophthalmology and Optometry China

Endpoints for Neuroprotection Clinical Trials in Glaucoma

Intraocular pressure lowering is currently the only proven neuroprotective therapy for glaucoma. Looking to the future, there is potential for new development: the FDA is open to using structural endpoints in clinical trials of new glaucoma drugs. Ora’s Chief Medical Officer Gustavo De Moraes, MD, PhD, MPH, recently spoke on this topic at the International Congress of Ophthalmology and Optometry China. Watch the video to learn more about the evolution of research in this critical area.

DOWNLOAD POWERPOINT